The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors

NCT04469582 | Unknown DMC

• 1 other identifier: BP-DPP4is
• Study Type: observational
• Target: 113
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators conducted a prospective study which included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019. 113 consecutive patients with BP were identified. The investigators included the patients with type 2 diabetes and investigated the percentage of patients who were under treatment with DPP4-is. The specific DPP4-i prescribed was also documented.Medical information including patients' age, sex, other comorbidities and concomitant medications were also recorded. Furthermore, the investigators evaluated the effect of different types of treatment (topical steroids, systemic corticosteroids, immunosuppressive agents) on bullous pemphigoid.

Conditions

Bullous Pemphigoid

Outcome Measures

Primary Outcomes (1)

• Τhe correlation between the use of DPP-4is and the development of Bullous pemphigoid

  The investigators assessed the percentage of patients who were under treatment with DPP4-is among patients with bullous pemphigoid

  baseline

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

In the study included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019.

You may qualify if:

• biopsy proven bullous pemphigoid
• severe bullous pemphigoid
• recent manifestation of bullous pemphigoid (last four months)

You may not qualify if:

• non bullous pemphigoid
• presentation of bullous pemphigoid more than four months
• treatment with DPP4is more than two years

Sponsors & Collaborators

• University of Athens: lead

Study Sites (1)

"Attikon" University General Hospital

Athens, Attica, 12462, Greece

Location

MeSH Terms

Conditions

Pemphigoid, Bullous

Condition Hierarchy (Ancestors)

Skin Diseases, Vesiculobullous; Skin Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Vaia Lambadiari, MD,PhD

  2nd department of internal medicine,University of Athens,Greece

  PRINCIPAL INVESTIGATOR

• Evangelia Papadavid, MD,PhD

  2nd department of dermatology and venereology,University of Athens, Greece

  PRINCIPAL INVESTIGATOR

• Aikaterini Kountouri, MD

  2nd department of internal medicine,University of Athens,Greece

  PRINCIPAL INVESTIGATOR

• Emmanouil Korakas, MD

  2nd department of internal medicine,University of Athens,Greece

  PRINCIPAL INVESTIGATOR

• Sofia Theotokoglou

  2nd department of dermatology and venereology,University of Athens, Greece

  PRINCIPAL INVESTIGATOR

• Konstantinos Theodoropoulos

  2nd department of dermatology and venereology,University of Athens, Greece

  PRINCIPAL INVESTIGATOR

• Ignatios Ikonomidis, MD,PhD

  2nd department of cardiology,University of Athens,Greece

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate professsor of Cardiology

Study Record Dates

• First Submitted: July 9, 2020
• First Posted: July 14, 2020
• Study Start: April 1, 2009
• Primary Completion: September 9, 2020
• Study Completion: December 31, 2020
• Last Updated: September 23, 2020

Record last verified: 2020-09

Locations

GR (1)